Sandoz: Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva (ustekinumab─ttwe) in the US. From February 24, the medicine is commercially available to patients across the US.